Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$57.89

-3.85 (-6.24%)

, SMMT

Summit Therapeutics

$11.92

-1.45 (-10.85%)

10:42
10/10/16
10/10
10:42
10/10/16
10:42

Sarepta and Summit Therapeutics to hold a joint conference call

Sarepta and Summit Therapeutics discuss their exclusive license and collaboration agreement granding Sarepta rights in Europe, as well as Turkey and the Commonwealth of Independent States to Summit's utrophin modulator pipeline, including its lead clinical candidate, Ezutromid for treating Duchenne Muscular Dystrophy in a joint conference call to be held on October 10 at 12 pm.

SRPT

Sarepta

$57.89

-3.85 (-6.24%)

SMMT

Summit Therapeutics

$11.92

-1.45 (-10.85%)

  • 11

    Oct

  • 06

    Nov

SRPT Sarepta
$57.89

-3.85 (-6.24%)

09/28/16
JMPS
09/28/16
NO CHANGE
JMPS
Street underestimating price of Sarepta drug, says JMP Securities
JMP Securities analyst Liisa Bayko expects the price of Sarepta's Exondys 51 drug will be above the company's projected annual net price of $300,000. She thinks that the price will come in "closer to $538,000 per year on a gross basis, $457,000 net of discounts and compliance." The analyst raised her price target on the shares to $90 from $60 and keeps an Outperform rating on the stock.
10/04/16
PIPR
10/04/16
NO CHANGE
Target $68
PIPR
Overweight
Piper Jaffray ups Sarepta target to $68 on Summit deal
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics (SRPT) to $68 from $64 after the company licensed Summit Therapeutics' (SMMT) ezutromid to treat Duchenne Muscular Dystrophy in Europe, Turkey and the Commonwealth of Independent States. The deal is a smart way for Sarepta to capitalize on its lead in DMD with the recent FDA approval of Exondys51, Tenthoff tells investors in an intraday research note. His new price target of $68 reflects the value of ezutromid. Tenthoff reiterates an Overweight rating on Sarepta. The stock is up 1% to $61.61 in late morning trading. Summit is up 94%, or $8.17, to $16.82.
10/05/16
ADAM
10/05/16
NO CHANGE
Target $28
ADAM
Buy
Summit Therapeutics price target raised to $28 from $14 at Canaccord
Canaccord analyst Arinda Lee raised her price target on Summit Therapeutics (SMMT) to $28 from $14 following the announcement of its collaboration and licensing agreement with Sarepta Therapeutics (SRPT). The deal calls for Sarepta to gain EU commercialization rights to Summit's pipeline of oral utrophin modulators for all patients with Duchenne muscular dystrophy. Lee reiterated her Buy rating Summit Therapeutics shares.
10/07/16
BARD
10/07/16
NO CHANGE
Target $102
BARD
Outperform
Anthem policy does not mean insurer not covering Sarepta drug, says Baird
Baird analyst Brian Skorney noted Anthem (ANTM) has categorized Sarepta (SRPT) Duchenne muscular dystrophy drug Exondys 51 as "not medically necessary" in a new coverage policy, but he cautions this "does not mean that Anthem is not covering the drug." The analyst explains that the policy means prior authorization requirements may be stricter, but he "highly doubts" that eligible patients will be denied coverage. Skorney, who adds that other large insurers appear to have favorable coverage for the drug, keeps an Outperform rating and $102 price target on Sarepta shares.
SMMT Summit Therapeutics
$11.92

-1.45 (-10.85%)

10/04/16
NEED
10/04/16
NO CHANGE
Target $30
NEED
Buy
Summit Therapeutics price target raised to $30 from $22 at Needham
Sarepta Therapeutics (SRPT) and Summit Therapeutics (SMMT) announced this morning that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States, to Summit's utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy.
10/04/16
JMPS
10/04/16
NO CHANGE
JMPS
Outperform
Summit Therapeutics price target raised to $42 from $24 at JMP Securities

TODAY'S FREE FLY STORIES

WMT

Wal-Mart

$72.14

0.43 (0.60%)

, TGT

Target

$65.62

-0.32 (-0.49%)

15:35
02/23/17
02/23
15:35
02/23/17
15:35
Periodicals
Trump supportive of border tax in Reuters interview »

Headlines crossing…

WMT

Wal-Mart

$72.14

0.43 (0.60%)

TGT

Target

$65.62

-0.32 (-0.49%)

HD

Home Depot

$145.17

-0.081 (-0.06%)

LOW

Lowe's

$76.40

-0.4 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 05

    Mar

  • 06

    Mar

  • 14

    Mar

  • 15

    Mar

  • 19

    Mar

OLED

Universal Display

$71.25

-0.3 (-0.42%)

15:35
02/23/17
02/23
15:35
02/23/17
15:35
Options
Universal Display options imply 12.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

15:35
02/23/17
02/23
15:35
02/23/17
15:35
Hot Stocks
Breaking Hot Stocks news story  »

Harmony Merger trading…

HRMN

Harmony Merger Corp.

$10.24

0.0499 (0.49%)

15:35
02/23/17
02/23
15:35
02/23/17
15:35
Hot Stocks
Breaking Hot Stocks news story on Harmony Merger Corp. »

Harmony Merger Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORI

Old Republic

$20.95

-0.07 (-0.33%)

15:27
02/23/17
02/23
15:27
02/23/17
15:27
Hot Stocks
Old Republic raises dividend, extends shareholder rights plan, expands board »

Old Republic announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPWR

SunPower

$8.46

-0.12 (-1.40%)

15:26
02/23/17
02/23
15:26
02/23/17
15:26
Options
SunPower call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXMD

TherapeuticsMD

$5.73

0.06 (1.06%)

15:24
02/23/17
02/23
15:24
02/23/17
15:24
Recommendations
TherapeuticsMD analyst commentary  »

TherapeuticsMD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 01

    Mar

  • 21

    Mar

  • 07

    May

USB

U.S. Bancorp

$55.38

0.07 (0.13%)

15:20
02/23/17
02/23
15:20
02/23/17
15:20
Periodicals
Trump considers outgoing U.S. Bancorp CEO for Fed board seat, Bloomberg says »

President Trump is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

  • 15

    Mar

CENX

Century Aluminum

$14.48

-0.77 (-5.05%)

15:20
02/23/17
02/23
15:20
02/23/17
15:20
Options
Century Aluminum options imply 12.4% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

ICPT

Intercept

$122.79

-2.66 (-2.12%)

15:19
02/23/17
02/23
15:19
02/23/17
15:19
Recommendations
Intercept analyst commentary  »

Intercept shares defended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 06

    Mar

$NSD

NASDAQ Market Internals

15:18
02/23/17
02/23
15:18
02/23/17
15:18
Technical Analysis
NASDAQ Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:17
02/23/17
02/23
15:17
02/23/17
15:17
Technical Analysis
NYSE Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VASC

Vascular Solutions

, TFX

Teleflex

$183.34

-0.67 (-0.36%)

15:16
02/23/17
02/23
15:16
02/23/17
15:16
Hot Stocks
Gabelli liquidates stake in Vascular Solutions »

As a result of the…

VASC

Vascular Solutions

TFX

Teleflex

$183.34

-0.67 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

UPS

UPS

$105.01

-0.615 (-0.58%)

15:12
02/23/17
02/23
15:12
02/23/17
15:12
Hot Stocks
Teamsters says UPS mechanics seek mediation release »

The Teamsters union…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

KMI

Kinder Morgan

15:11
02/23/17
02/23
15:11
02/23/17
15:11
Options
Notable call buying in Kinder Morgan »

Notable call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$80.74

1.12 (1.41%)

15:06
02/23/17
02/23
15:06
02/23/17
15:06
Hot Stocks
Medtronic reports presentation of data on Solitaire stent retriever »

Medtronic said data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 07

    Mar

  • 17

    Mar

  • 21

    Mar

ACIA

Acacia Communications

$62.22

-4.32 (-6.49%)

15:05
02/23/17
02/23
15:05
02/23/17
15:05
Options
Acacia Communications options imply 14.2% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 04

    Apr

  • 05

    Apr

HRMN

Harmony Merger Corp.

$10.24

0.0499 (0.49%)

15:04
02/23/17
02/23
15:04
02/23/17
15:04
Hot Stocks
Harmony Merger receives termination of merger pact from MUNDOmedia »

Harmony Merger announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$50.26

-0.08 (-0.16%)

15:02
02/23/17
02/23
15:02
02/23/17
15:02
Hot Stocks
Prologis raises annualized dividend level by 5% to $1.76 per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

FDX

FedEx

$191.42

-2.4099 (-1.24%)

15:01
02/23/17
02/23
15:01
02/23/17
15:01
Hot Stocks
FedEx extends relationship with Joe Gibbs Racing »

FedEx announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

KATE

Kate Spade

$23.60

-0.24 (-1.01%)

15:01
02/23/17
02/23
15:01
02/23/17
15:01
Options
In the money call buying in Kate Spade »

In the money call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TANH

Tantech Holdings

$1.80

-0.04 (-2.17%)

15:00
02/23/17
02/23
15:00
02/23/17
15:00
Hot Stocks
Tantech Holdings CEO sees operating profits growing 'substantially faster' »

Tantech Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
02/23/17
02/23
15:00
02/23/17
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

CME

CME Group

$122.51

1.46 (1.21%)

14:59
02/23/17
02/23
14:59
02/23/17
14:59
Hot Stocks
CME Group reports new record for Fed Fund futures contracts »

CME Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

PI

Impinj

$28.49

-0.34 (-1.18%)

14:57
02/23/17
02/23
14:57
02/23/17
14:57
Technical Analysis
Impinj spikes higher, levels to watch »

Shares were last up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.